Cochrane · systematic review · CD006986
Acetylcholinesterase inhibitor treatment for myasthenia gravis
Mehndiratta, MM, Pandey, S, Kuntzer, T · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
2
No studies
1
Included studies
NR
No studies 1 · 33.3%Ungraded 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsIntranasal neostigmine compared with placebo for myasthenia gravis
Population: people with myasthenia gravis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improved muscle function various methods1 Intranasal neostigmine vs placebo | no estimate extracted | 10 participants | Very low Downgraded: imprecision |
Adverse events Intranasal neostigmine vs placebo | no estimate extracted | 1 study · 20 participants | Very low Downgraded: imprecision |
Change in impairment 1 to 14 days after the start of treatment ‐ not reported Intranasal neostigmine vs placebo | no estimate extracted | NR | No studies |